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Abstract: Alzheimer’s disease (AD) is the most common form of dementia, and it generally 
affects the elderly. It has been suggested that diet is an intensively modifiable lifestyle factor 
that might reduce the risk of AD. Because epidemiological studies generally report the potential 
neuronal protective effects of various micronutrients, the aim of this study was to perform a 
literature review on the major nutrients that are related to AD, including selenium, vitamins C 
and E, transition metals, vitamin D, B-complex vitamins, and omega-3 fatty acids.
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Introduction
Population aging is a worldwide phenomenon that results in changes in health pro-
files, including an increase in the predominance of chronic diseases. In addition, the 
prevalence of dementia is increasing; according to Ferri et al,1 4.6 million new cases 
arise every year, and if new prevention strategies are not implemented, the number of 
affected people will exceed 81 million by the year 2040.
Alzheimer’s disease (AD) is the main cause of dementia in the elderly. The disease 
is clinically characterized by progressive and irreversible cognitive deficits and behav-
ioral alterations that affect memory and learning ability, activities of daily living, and 
quality of life. The major risk factor for the development of AD is aging, although some 
genetic risk factors are also known. Approximately 1% of people aged 65–69 years, 
3% of people aged 70–74 years, 6% of people aged 75–79 years, 12% of people aged 
80–84 years, and 25% of people aged 85 and over will develop AD.2 Cerebrovascular 
disease and a history of diabetes, hypertension, smoking, obesity, and elevated lipid 
levels have been found to increase the risk of AD. A healthy lifestyle is associated 
with lower rates of dementia; higher education, mentally stimulating activities, and 
involvement in mental, social, and productive activities play important roles as well.3,4 
Because pharmacological treatments for AD are limited, there is a growing interest in 
understanding how diet could mitigate the risk and progression of AD. Associations 
between diet and cognitive decline are strongly suggested in numerous epidemiologi-
cal studies and interventional trials, although it is difficult to establish whether diet is 
a primary factor. However, among modifiable risk factors, nutrition seems to be the 
most important factor because nutritional status might alter other risk factors.5
AD patients usually have insufficient levels of specific nutrients, and low intake 
of these nutrients is associated with an increased risk of developing AD. However, 
AD is associated with progressive changes in eating behaviors. The mesial temporal 
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cortex, which is involved in memory and food intake control, 
is affected by dementia. Disturbances affecting this region 
involve serotonin, dopamine, and epinephrine neurotransmis-
sion, which in turn are involved in eating behavior regulation 
and could result in appetite loss and refusal to eat, decreasing 
food intake.6,7
Epidemiological studies generally report the poten-
tial neuronal protective effects of various micronutrients, 
including B-complex vitamins, antioxidants, vitamin D, and 
polyunsaturated fatty acids. These nutrients are related to the 
stimulation of neural plasticity and to the reduction in ongo-
ing neurodegenerative processes; they also show an ability 
to reduce the pathological burden in the brain.8,9 Therefore, 
the objective of this study was to perform a literature review 
on the major nutrients that are related to AD, focusing on the 
importance of their deficiencies in AD progression and on 
strategies for prevention and/or treatment of AD. This work 
addresses the main aspects concerning antioxidants, includ-
ing selenium (Se) and vitamins C and E; transition metals 
such as zinc (Zn), iron (Fe) and copper (Cu); vitamin D; 
B-complex vitamins; and omega-3 fatty acids.
Antioxidants
Oxidative stress plays a central role in the initiation and 
progression of AD. The brain is particularly vulnerable to 
oxidative damage because of its elevated oxygen utilization 
rate; high content of polyunsaturated lipids that are suscep-
tible to lipid peroxidation; accumulation of transition metals 
such as Fe, Cu, and Zn, which are capable of catalyzing the 
formation of reactive oxygen species (ROS); and relatively 
poor concentrations of antioxidants.10–12 Moreover, the aging 
process implies morphological and physiological changes in 
the brain, resulting in higher ROS production and a decrease 
in antioxidant capacity.12,13
Amyloid beta-protein (Aβ) is the major amyloid protein 
in AD. This protein inhibits the electron transport chain in 
mitochondria, decreases the respiratory rate, induces the 
release of ROS and might also cause neurotoxicity through 
the direct production of ROS by its interaction with transition 
metals and lipid membranes.14
To combat the cytotoxic activities of ROS, cells are 
equipped with a variety of antioxidant defenses, including 
antioxidant enzymes such as catalase and glutathione peroxi-
dase, as well as free-radical-scavenging chemicals such as 
ascorbate and vitamin E. Antioxidants can act by minimizing 
or even removing oxidants such as ROS and metal ions, or by 
interfering with the oxidation chain reactions and optimizing 
the cell’s own antioxidant defenses.15
Selenium
Se is an important trace element for the body, and its essential 
nature is due to the necessity of selenocysteine incorporation 
in some selenoproteins. Among Se functions, its antioxidant 
role, played through selenoprotein P (SePP) and the enzymes 
glutathione peroxidase (GPx) and thioredoxin reductase, has 
been emphasized in previous studies.16
Studies that evaluate the relationship between Se levels 
and cognitive decline suggest that a lack of Se might increase 
the risk of dementia;17,18 however, the results of various stud-
ies are contradictory. Cardoso et al19 and Vural et al20 verified 
that AD patients had lower Se levels than healthy elderly 
people, whereas Ceballos-Picot et al21 found an increase in 
plasma Se levels in AD patients compared to a control group. 
Moreover, Smorgon et al,22 when evaluating the association 
between trace elements and cognitive function decline in 
different groups, found a direct correlation between the 
plasma Se concentration and cognitive function. Compared 
to the control group, AD patients showed reduced Se plasma 
concentrations.
From an animal model, it has been observed that the 
Se supply to the brain depends on SePP. SePP is the major 
Se transporter and is responsible for up to 60% of the total 
serum Se concentration. The role of SePP as a transporter is 
related to its capacity to link to ten selenocysteine residues 
and to its extracellular location. Thus, Se enters the brain 
through an interaction between SePP and a receptor, after 
which time it is released intracellularly for the synthesis of 
selenoproteins.23,24
It is believed that SePP synthesis occurs in the brain; 
SePP is then secreted into the cerebrospinal liquid, where it 
associates with neuronal cells or remains available for other 
tissues, acting as a selenium supply. Biosynthesis, cellular 
storage, and reuptake of SePP originates the “SePP cycle.” 
This process is consistent with the fact that SePP activity and 
expression are maintained in the brain even in situations of 
organic depletion once the Se status in the brain is not depen-
dent on body Se levels. SePP also plays an antioxidant role, as 
it has the ability to reduce phospholipid hydroperoxides and 
to inhibit the oxidation of low-density lipoproteins.23,24
Lu et al25 and Miller et al26 suggest that SePP levels tend 
to increase in aging and in AD patients. Bellinger et al27 iden-
tified the presence of SePP aggregated to amyloid plaques 
and to neurofibrillary tangles, raising two hypotheses: SePP 
might act in a direct way as an antioxidant, or in an indirect 
way by transporting Se for the synthesis of other antioxidant 
selenoproteins. Accordingly, Takemoto et al28 observed in 
vitro that neuronal cells that were exposed to the oxidant 
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effects of amyloid plaques were protected in the presence 
of SePP.
GPx constitutes a selenium-dependent five-enzyme 
family. These enzymes are expressed in neurons and glia cells, 
and their main function is the elimination of peroxides.23,29 
GPx are involved in a sequence of reactions that aim to reduce 
hydrogen peroxides and organic hydroperoxides.30,31 These 
enzymes obtain electrons via glutathione, but differ from 
each other regarding their specificity to different substrates 
of hydroperoxides and their tissue distributions.32
Some studies suggest that cognitive decline is associ-
ated with a decrease in GPx activity. Cardoso et al19 and 
Vural et al20 observed lower activity of this enzyme fam-
ily in AD patients compared to healthy individuals, while 
Parudariu et al33 verified that dementia patients and patients 
with mild cognitive decline presented lower GPx1 activity.
Beef, chicken, fish, eggs, and wheat are considered good 
sources of Se. However, the amounts of Se in such foods 
reflect its concentration in the soil, so the same kind of food 
could present different Se concentrations depending on its 
origin.34,35 The Brazil nut ranks as the best Se source due to 
its high concentration; the levels of Se in Brazil nuts vary 
from 8 µg/g to 83 µg/g, and Se is highly bioavailable in this 
food.35
Thomson et al35 achieved an improvement in Se status in 
healthy individuals after supplementing them with two Brazil 
nuts daily for 12 weeks. Other studies have verified that the 
daily ingestion of one Brazil nut was effective in restoring 
Se status in dialysis patients, severely obese women, and 
the elderly.36–38
Brazil nut consumption may also be effective in improving 
Se status in patients with AD, and this improvement could be 
an important therapeutic target regarding the maintenance of 
these patients’ cognitive functions. Depending on the region 
where the nuts were grown, it is safe to recommend the intake 
of one to two nuts daily for the purpose of reaching adequate 
blood Se levels, unless the patient presents allergies.
Vitamins C and E
Vitamin E (tocopherols and tocotrienols) is the major mem-
brane-bound fat-soluble antioxidant, and vitamin C (ascorbic 
acid) is an important water-soluble antioxidant that protects 
low-density lipoproteins from oxidation.39 These vitamins act 
synergistically because oxidized α-tocopherol is reduced by 
ascorbate, leading to its regeneration.40
In vitro studies suggest that antioxidants, including 
 vitamins C and E, may prevent hyperphosphorylated tau 
protein dysfunction. Additionally, vitamin E has been related 
to a reduced rate of neuronal death induced by Aβ protein in 
cultures of hippocampal and cortical cells.41
Studies have shown that vitamin E intake tends to be 
lower in AD patients,42,43 and the association between dietary 
vitamins C and E and dementia risk have yielded inconsistent 
results based on short-term and long-term follow-up periods. 
Morris et al44 and Devore et al45 associated a higher intake 
of vitamin E but not vitamin C with a lower long-term risk 
of dementia over a mean follow-up period of 2 years and 
9.6 years, respectively. Luchsinger and Mayeux46 found no 
relationship between the intake of vitamins C and E from 
food or supplements and the risk of developing AD during 
4 years of follow-up time. In a cross-sectional study, Gu et al9 
evaluated the association between nutrient intake and plasma 
Aβ levels in a cognitively healthy elderly population. Their 
data suggest that vitamins such as C, E, D, B12, and folic 
acid might have no association with Aβ-related mechanisms 
because the intake of these vitamins did not affect plasma Aβ 
levels. However, data from the Cache County Study have 
shown that the combined use of vitamin E and C supplements 
was associated with a reduced occurrence of AD. Interestingly, 
there was no reduction in AD risk with isolated vitamin E or C 
intake or with multivitamins, which may be justified by the 
dependence between these vitamins in scavenging ROS.47 
These observations were different from those reported in the 
Adult Changes in Thought study, which showed no effect of 
the supplemental use of vitamins E or C on reducing the risk 
of dementia or AD for over 5 years of follow-up time.48
According to Brewer,49 the controversial results found 
in various studies could be justified by incorrect dosage and 
timing, unbalanced monotherapy, or incorrect targets. The 
dosage should be evaluated to obtain a decreased plasma 
oxidative redox potential, and it is essential to associate 
water-soluble electron acceptors with vitamin E therapy 
to improve systemic ROS removal. Oxidative stress is one 
mechanism that is associated with AD pathogenesis, but other 
pathways should be targeted as well. Furthermore, AD can 
probably not be reversed by supplementation therapy, so AD 
prevention should be prioritized.
Moreover, an individual’s early evaluation and the identi-
fication of prescribed medicines are fundamentally important 
to determine the presence of interactions that could interfere 
with nutrient bioavailability. The literature is not consistent 
in reporting the benefits of antioxidant supplementation 
(they do not establish a safe or effective dosage), and it is 
believed that this measure should not be recommended for the 
purpose of preventing or treating AD.50 However, the intake 
of antioxidant-rich foods should be prioritized because they 
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contain important components and phytochemical substances 
that interact with each other, potentiating their beneficial 
effects.51,52 Furthermore, because the vitamin E found in 
supplements is usually synthetic and is composed of only one 
of eight natural isoforms (α-tocopherol), dietary sources of 
vitamin E should be used over supplements to provide differ-
ent combinations of tocopherol and tocotrienol forms, which 
might play an important role in preventing AD.48,53
Transition metals: zinc, iron,  
and copper
Zn is one of the most important minerals for human 
metabolism. The versatility of its physicochemical character-
istics is the basis of its vast participation in the metabolism 
of carbohydrates, proteins, lipids, and nucleic acids. Zn also 
plays an important role in polynucleotide transcription and, 
consequently, in the control of gene expression and other fun-
damental biological mechanisms. Zn contributes to normal 
growth and development, membrane integrity, antioxidant 
defenses, immunity, appetite maintenance, scarring and night 
vision.54 In a study involving the human genome database, 
it was estimated that approximately 10% of the human pro-
teome codes for proteins that are potentially linked to Zn.55 
In the central nervous system, Fe is required as a cofactor 
for oxidative phosphorylation, neurotransmitter production, 
nitric oxide metabolism, and oxygen transport, and Cu is an 
essential cofactor for neurotransmitter synthesis and plays 
an important role in neuroprotection via the cytosolic Cu/Zn 
superoxide dismutase.56
The brain controls the homeostasis of these metals as 
part of its physiology because those ions play important 
roles in neuronal activities. However, it is believed that 
alterations in metal metabolism at the cerebral level may be 
associated with AD. Those alterations probably participate 
in cascades of pathogenic events, which eventually cause 
clinical symptoms.56 In cultured neurons, metals seem to 
mediate Aβ toxicity through the modulation of oxidative 
stress caused by that protein. Aβ has a strong affinity for Cu2+, 
Zn2+, and Fe3+, and is able to reduce Cu2+ to Cu+ and Fe3+ to 
Fe2+, producing free radicals that increase Aβ toxicity.57
High levels of Cu can be found in the senile plaques of 
AD patients, and studies have shown that this metal mediates 
Aβ aggregation and increases this protein’s oxidant capacity 
in an electron transfer reaction that reduces Cu2+ to Cu+.58,59 
The Aβ precursor protein (APP) also has a high affinity for 
Cu2+, and higher Cu levels promote an increase in intracel-
lular APP, which leads researchers to speculate that APP 
could act as a Cu transporter.60 The involvement of Fe in the 
formation of senile plaques resembles that of Cu. Finefrock 
et al57 and Bolognin et al61 showed that in its free form, this 
mineral is capable of triggering Aβ aggregation, enhancing 
its neurotoxicity.
Researchers suggest that a change could occur in the 
transport and turnover of Cu in the presence of AD, which 
promotes an altered distribution of the metal among the vari-
ous compartments and an accumulation in the central nervous 
system. Some studies have shown that the levels of free Cu 
(not bound to ceruloplasmin) are increased in the blood of AD 
patients and are negatively correlated with cognitive function, 
although the level of total Cu is not necessarily altered.62–64 
Cu can be found in an organic form (bound to proteins) and 
in an inorganic form (as an unbound salt). These two forms 
differ regarding their sources, with the organic form found 
in foods, and the inorganic form found in water from Cu 
pipes and in most supplements. Regarding metabolism, the 
organic form is naturally and safely processed by the liver, 
and the inorganic form at least partially bypasses the liver 
and contributes immediately to the free Cu pool; it is also 
able to cross the blood–brain barrier easily.64,65 Thus, it is 
believed that the use of Cu piping could be a public health 
issue due to its relationship with a loss of cognitive function 
and worsening of AD.
Studies have shown that free extracellular Zn might 
increase Aβ adhesivity, interfering with its catabolism and 
inducing its deposition through structural destabilization and 
transformation.66–69 This action is related to the involvement 
of Zn in the synthesis and processing of APP. The synthesis 
of this protein is regulated by Zn-containing transcription 
factors.70 Processing by the nonamyloidogenic pathway, which 
is catalyzed by one alpha-secretase and results in the formation 
of soluble APP, a neurotrophic factor,71 may be influenced by 
Zn because APP presents a binding site for this metal at the 
position where alpha-secretase catalyzes the processing of 
APP. It has recently been proposed that Aβ deposits promote 
Zn sequestration in vulnerable extraneuronal regions that are 
important for memory. This process depletes intraneuronal Zn 
concentrations and promotes microtubule destabilization via 
the reduction of electrostatic interactions or aberrant ligation 
between tubulin, as well as the formation of neurofibrillary 
tangles with consequent neuronal degeneration.72
Despite the attention paid to Zn in AD, the role of food 
modification regarding this nutrient in the reduction of 
disease advancement is poorly understood. Although they 
did not find conclusive evidence that could guide dietary Zn 
modifications to reduce the risk of AD, Loef et al73 claim, in 
a systematic review, that reduced Zn concentrations in AD 
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patients might be related to disease risk. They suggest that 
a greater emphasis should be placed on an adequate supply 
of Zn to the elderly, either through increased consumption 
of Zn-containing food sources such as seafood, meat, nuts, 
and whole grains, or through supplementation in situations 
where food intake is insufficient, which is widely observed 
among AD patients. Before introducing Zn supplementation, 
a biochemical evaluation of Zn status is recommended. There 
is no consensus regarding the best biomarker for this analysis; 
however, plasma is a good option to verify a patient’s Zn 
status. Once a deficiency is identified, Zn supplementation 
can be safely performed in the amounts recommended by the 
Institute of Medicine,74 taking into account data from Lowe 
et al,75 which show that every doubling of Zn intake leads to 
a 6% difference in the Zn serum or plasma concentration.
Vitamin D
Currently, vitamin D deficiency is widespread and prevalent 
in all population groups, with approximately 1 billion people 
classified as deficient (,20 ng/mL) or with insufficient 
concentrations of 25-hydroxyvitamin D (,30 ng/mL). It 
should be noted that a large proportion of the senile popula-
tion suffers from this deficiency.76,77 In addition to rickets, 
vitamin D deficiency is a risk factor for bone disorders such 
as osteopenia, osteomalacia, and osteoporosis, which implies 
a greater risk of fractures in different age groups.78,79
More recently, with the advancement of molecular meth-
odologies, it has been observed that vitamin D might be 
metabolized in several other tissues, including the pancreas, 
prostate, breast, colon, kidneys, and macrophages, in addi-
tion to those previously known and implied in the control of 
bone homeostasis. Therefore, this vitamin deficiency could 
be related to other pathophysiological processes that are 
extremely relevant to public health.76
Given the simultaneous prevalence of vitamin D and 
dementia in the elderly population, there has been a search 
for clarification about the possible role of this nutrient in 
the etiology of such diseases.80 In addition to the afore-
mentioned tissues, it has been reported that vitamin D 
presents a high binding affinity in several brain regions, 
including neurons, glial cells, macrophages, spinal cord, 
and the peripheral nervous system.81 The identification of 
vitamin D receptor expression and of 1-α-hydroxylase – the 
enzyme responsible for vitamin activation – in the human 
brain corroborates the importance of the vitamin as a neu-
roactive hormone with autocrine and paracrine functions, 
as well as the possibility of therapies for alterations that 
affect the brain.82
Cross-sectional and longitudinal studies of the associa-
tion between hypovitaminosis D and low dietary consump-
tion of this nutrient have demonstrated important results 
regarding the cognitive performance of the elderly. With 
regard to vitamin D deficiency, Annweiler et al83 verified that 
this deficiency, indicated by serum concentrations lower than 
10 ng/mL, was associated with a worse cognitive decline 
profile in a cohort of French women aged 75 years or older 
when compared to women with a normal vitamin status 
(serum concentration higher than 10 ng/mL) and comparable 
age. The results remained the same after adjusting for sev-
eral confounding variables. On the other hand, Slinin et al84 
found only a tendency toward an independent association 
between low serum concentrations of vitamin D (less than 
20 ng/mL) and a risk of cognitive decline in a population of 
over 1600 North American men aged 65 years or older after 
a mean follow-up period of 4.6 years, but only when indi-
viduals were evaluated with a Modified Mini-Mental State 
Examination. Another cross-sectional study performed by 
Llewellyn et al85 demonstrated that Italian individuals aged 
65 years or older with vitamin D serum concentrations below 
10 ng/mL and followed for 6 years presented a substantial 
relative risk of cognitive decline of 1.61 after adjusting for 
several variables (95% confidence interval [CI], 1.19–2.01; 
P = 0.02) compared to those with sufficient vitamin D serum 
concentrations ($30 ng/mL) when the subjects were evalu-
ated through the Mini Mental State Exam, and a relative risk 
of 1.32 (95% CI, 1.03–1.51; P = 0.05) when the subjects 
were evaluated through Trail-Making Test B. Breitling et al86 
verified that the cognitive performance (assessed through 
the Cognitive Telephone Screening Instrument) of a German 
elderly population that was followed for 5 years and adjusted 
for important confounding variables (age, educational level, 
body mass index, and season of the year) was significantly 
lower in women in the lowest quartile of vitamin D serum 
concentrations (odds ratio [OR]: 2.1, 95% CI, 0.4–3.9; 
P = 0.018); very similar results were found for the men in 
the population.
However, with regard to dietary vitamin D intake, a cross-
sectional study with more than 5000 French elderly women 
verified that those women with inadequate weekly vitamin D 
dietary ingestion (,35 µg/week) presented a significantly 
decreased cognitive performance compared to those women 
with adequate dietary ingestion ($35 µg/week) (OR = 1.30, 
95% CI = 1.04–1.63, P = 0.024) after adjusting for several 
confounding factors.87
Studies have speculated about two possible directions 
of the relationship between vitamin D concentration and 
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cognition. Despite the uncertainty about the causality of this 
association, it is suggested that cognitive function impairment 
promotes low vitamin dietary ingestion and/or impairs the 
individual’s exposure to the sun, which would result in low 
vitamin serum concentrations. Nevertheless, given the results 
of these studies, it could be suggested that the association of 
hypovitaminosis D with diseases that promote alterations in 
cognitive performance, including AD, could be understood 
as a causal relationship in which vitamin D plays a neuro-
protective role.77
In a review of several studies, Kalueff and Tuohimaa81 
indicate that vitamin D neuroprotective functions are related 
to factors such as a reduction in calcium toxicity, modulation 
of glutathione metabolism, direct antioxidant effects, reduc-
tion in nitric oxide synthesis, induction of neurotrophins and 
neuritogenesis, modulation of cytokine release, anti-ischemic 
actions, and neuronal protection against hormone-induced 
cell death. It has also been described that vitamin D stimu-
lates clearance and Aβ phagocytosis by macrophages of AD 
patients and protects these immune cells against apoptosis by 
regulating both nongenomic (extranuclear protein functions) 
and genomic (gene expression) signaling.88,89 Attention has 
also been given to the actions of the klotho protein, which 
seems to regulate vitamin D concentrations in addition to 
interacting with this vitamin in the regulation of cerebral 
functions and the aging process.81
The results of studies aiming to evaluate the effects 
of vitamin D on cognition are controversial.90,91 There 
have been discussions about the methods used to evaluate 
cognition, the intervention time and, mainly, the dose 
and form of vitamin D used because the literature clearly 
shows that vitamin D3 (cholecalciferol) is more bioavailable 
than vitamin D2 (ergocalciferol).91 Vitamin D supplementation 
is advised to increase the levels of this vitamin and to 
maintain the 25-hydroxyvitamin D concentration between 
30 ng/mL and 80 ng/mL.92 Studies show an increase in 
serum 25-hydroxyvitamin D concentration from 0.64 ng/mL 
to 0.79 ng/mL (1.6 to 1.97 nmol/L) per microgram of daily 
vitamin D3 intake. This information is important to guide 
the recommended supplementation, and from these data, it 
is suggested that vitamin D supplementation for the elderly 
with AD is preferably performed at doses between 800 IU 
and 4000 IU, which is the upper level set by the Institute 
of Medicine.93 The consumption of supraphysiological 
doses does not promote a significant impact on overall 
cognitive performance.77 There seems to be no benefit of 
exaggerated consumption of vitamin D supplements on 
cognitive  performance, and the idea that hypercalcemia 
induced by excessive vitamin D intake could increase the risk 
of dementia should also be taken into consideration.
B-complex vitamins
Among B-complex vitamins, niacin, thiamin, and vitamin B12 
present well established relationships with the deterioration 
of mental status because all three vitamins are related to 
neurological syndromes.94
Regarding vitamin B12 deficiency, 40% of patients 
develop neuropsychiatric syndromes, which are characterized 
by progressive and variable spinal cord, peripheral nerve, and 
brain damage. Initial sensory impairments occur, such as 
distal and symmetric paresthesia of the lower limbs, which 
are often associated with ataxia.95 This deficiency is even 
more important in the elderly, who are more susceptible due 
to factors such as poor vitamin absorption from foods (chiefly 
due to gastric atrophy) and pernicious anemia, which is an 
autoimmune disease that is characterized by the destruction 
of the gastric mucosa. The elderly frequently suffer from 
this hypovitaminosis, and institutionalized and sick elderly 
patients can present a prevalence of 30%–40%, depending 
on the considered reference values and biomarkers.96
Two important neurological alterations, Wernicke–
Korsakoff syndrome and pellagra, are associated with thiamine 
and niacin deficiency, respectively. The first promotes damage 
to the central and peripheral nervous systems, with sight and 
muscular coordination problems, and subsequent memory loss, 
confabulations, and hallucinations. Pellagra is characterized 
by dementia, diarrhea, and dermatitis symptoms, in addition to 
alterations in the central nervous system, such as neurasthenia 
and psychosis symptoms including disorientation, memory 
loss, and confusion.97
Although folic acid is not directly related to neurological 
disease, there is strong interest in this compound, as well as 
in vitamin B12, regarding dementia due to the fact that both 
nutrients are cofactors in homocysteine metabolism. Folic 
acid deficiency could reduce the concentration of acetyl-
choline (a deficient neurotransmitter in AD), or it could be 
related to a higher oxidative stress level.94
Prospective observational studies have shown that 
homocysteine total plasma concentrations show a strong 
relationship to the risk of dementia and AD, and an increase 
of 5 µmol/L in the homocysteine concentration increases the 
risk of AD by 40%, even after adjusting for variables such as 
age, gender, apolipoprotein E (ApoE) genotype and serum 
folate, vitamin B6, and vitamin B12 concentrations.98
One study showed that in Italian individuals (4 years 
of follow-up), high homocysteine plasma concentrations 
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and reduced folic acid serum concentrations are indepen-
dent predictors of dementia and AD. In individuals with 
hyperhomocysteinemia, the risk of developing dementia 
was 2.08 (95% CI 1.31–3.30, P = 0.002), and the risk of 
developing AD was 2.11 (95% CI 1.19–3.76, P = 0.011). 
Regarding serum folate levels, the risk of dementia and AD 
were 1.87 (95% CI 1.21–2.89, P = 0.005) and 1.98 (95% 
CI 1.15–3.40, P = 0.014), respectively, in individuals with 
reduced values.99
Cognitive performance has been related to homocysteine 
total plasma concentrations. Elias et al100 verified a significant 
inverse association between homocysteine levels and multiple 
cognitive abilities, such as abstract reasoning; new verbal 
learning and memory; verbal and visual memory; concentra-
tion, scanning, tracking, and executive performance; visual 
organization; and object naming and language, in individuals 
aged 60 or older but not in younger individuals.
High homocysteine concentrations are strongly associ-
ated with worse neurobehavioral performance in an analysis 
of more than 1000 patients aged between 50–70 years. On 
average, an increase in homocysteine levels from the 25th 
percentile to the 75th percentile was associated with neu-
robehavioral tests compatible with an increase in age of 
4.2 years.101 On the other hand, there have been reports that 
high homocysteine levels are not associated with AD and 
cognitive decline.102
Despite a number of relevant results, Morris et al94 claim 
that the evidence related to associations of B-complex vita-
mins (mainly folate) with parameters of cognitive decline are 
weak, due chiefly to study limitations. However, the evidence 
related to homocysteine concentrations seem to be stronger, 
and there has been an effort to determine the mechanism of 
action of this substance in increased dementia and AD risks, 
as well as in a reduction in cognitive decline. It is speculated 
that cellular and vascular pathways are involved. Elevated 
total homocysteine levels are considered alteration mark-
ers in the one-carbon cycle, which is essential for adequate 
methylation in neurons. This effect occurs because homo-
cysteine works as a fundamental intermediate of methionine 
metabolism via a methylation cycle that requires vitamin B12, 
folate, and vitamin B6, and generates an activated methyl 
group in S-adenosylmethionine. S-adenosylmethionine 
works as a methyl group donor in nucleic acid, phospholipid, 
protein, myelin, and catecholamine methylation reactions. 
Other possible mechanisms of action include the accelera-
tion of aging through the shortening of telomere lengths; 
toxicity and neuronal dysfunction; calcium influx and ROS 
generation in hippocampal neurons; excitotoxic damage 
by glutamatergic N-methyl-D-aspartate receptor activation 
through homocysteic acid; protein homocysteinylation with 
consequent alterations in the function of Na+/K+/ATPase, and 
in the inhibition of its activity; and a direct interaction with 
Aβ, increasing its formation, and with Tau protein, promoting 
its hyperphosphorylation.103
Considering its role in the reduction of homocysteine 
plasma levels, it is possible that folate, vitamin B12, and 
vitamin B6 supplementation could reduce the risk of demen-
tia, allowing for healthy cerebral aging. However, some 
researchers are more cautious when addressing the possibility 
that folic acid supplementation might mask vitamin B12 defi-
ciency or exacerbate neurodegenerative decline. Some studies 
on supplementation present conflicting results. Aisen et al104 
did not find positive results regarding a reduction in cogni-
tive decline by supplementing individuals who presented 
mild to moderate AD with large amounts of B-complex 
vitamins (5 mg/day of folate, 25 mg/day of vitamin B6, and 
1 mg/day of vitamin B12) for 18 months, and they verified a 
large number of adverse effects related to depression in the 
treated group. On the other hand, Smith et al105 observed a 
significant reduction in the brain atrophy rate in elderly people 
with mild cognitive alterations who received supplementation 
with 0.8 mg/day of folic acid, 0.5 mg/day of vitamin B12, 
and 20 mg/day of vitamin B6 for 2 years.
According to Morris et al,94 considering the scarce 
scientific literature on this topic, it would be safer to avoid 
folic acid supplementation in case there is no evidence of 
a clear deficiency, in addition to a continued monitoring of 
vitamin B12 deficiency. Seshadri103 defends the need for 
thorough studies before confirming or refuting the idea that 
reductions in homocysteine concentrations (through lifestyle 
modifications or B-complex supplementation) might delay 
the beginning of cognitive performance decline or slow its 
progression. Seshadri103 also claims that the existing evidence 
about homocysteine action as a risk factor for AD seems too 
appealing to be discarded.
Omega 3
Omega-3 long-chain polyunsaturated fatty acids, including 
α-linolenic acid (ALA), eicosapentaenoic acid (EPA), and 
docosahexaenoic acid (DHA), are dietary fats that are incor-
porated into cell membranes and play a role in antiinflamma-
tory processes and in the viscosity of cell membranes. ALA 
can only be obtained from the diet, while DHA and EPA can 
be synthesized in the body by the desaturation and elongation 
of ALA.106 DHA is the most abundant lipid in the neuronal 
membrane, and EPA is involved in the modulation of mem-
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brane fluidity, synaptic plasticity, and increase in the number 
and affinity of receptors. EPA is the substrate for the produc-
tion of the antiinflammatory prostaglandin-3 and competes 
with arachidonic acid for incorporation into cell membrane 
phospholipids and for the active sites of cyclooxygenase 
enzymes.107 On the other hand, although arachidonic acid 
plays an essential role in synaptic function, when present in 
high concentrations, it acts as a second messenger in some 
processes involving apoptosis and the production of inflam-
matory substances. Thus, an imbalance between omega-3 
and omega-6 polyunsaturated fatty acids may result in an 
increased susceptibility to neuronal damage, as observed 
in AD.108–110 DHA and EPA are mainly found in foods such 
as fish oils and fatty fish, including salmon, tuna, and trout, 
whereas ALA is commonly found in vegetable oils such as 
soya, canola, and linseed oils, nuts, and in smaller quantities 
in seeds, vegetables, legumes, grains, and fruits.111
In the majority of analyzed cohorts, the results show 
that fish consumption is associated with a lower risk of AD 
development, either due to the effects of DHA or of EPA, 
or because it is considered a healthy behavioral and eating 
pattern.112
As an observational study example, Barberger-Gateau 
et al113 evaluated a cohort (n = 8085) of patients aged 
65 years or older with no dementia (The Three City Cohort 
Study). After a mean follow-up period of 3.48 years, they 
observed that weekly fish consumption presented an associa-
tion with reduced AD risk (hazard ratio [HR] = 0.65, 95% 
CI = 0.43–0.994; P = 0.047), even after adjusting for ApoE 
genotype, body mass index (BMI), and diabetes. The frequent 
consumption of fish also presented an association with a 
reduced risk of dementia development, but only in ApoE 
ε4 noncarriers, and even when adjustments for BMI and 
diabetes were performed (HR = 0.60, 95% CI = 0.40–0.90; 
P = 0.01). The regular consumption of omega-3 fatty acid 
was marginally associated with a reduced risk of dementia 
occurrence after adjusting for ApoE genotype, BMI, and 
diabetes (HR = 0.46, 95% CI = 0.19–1.11; P = 0.08), and the 
regular consumption of omega-6-rich oils, unaccompanied 
by omega-3 and fish consumption, has shown an association 
with a considerably increased risk of dementia development 
in ApoE ε4 noncarriers (HR = 2.12, 95% CI = 1.30–3.46, 
P = 0.003).
In a cross-sectional study on the association between the 
ingestion of several nutrients and Aβ40 and Aβ42 plasma 
levels in a healthy elderly population (above age 65), Gu et al9 
verified that the highest omega-3 intake level was  associated 
with lower Aβ40 and Aβ42 concentrations, even after adjust-
ing for age, gender, ethnicity, educational level, caloric intake, 
ApoE genotype, and recruiting period.
Randomized, placebo-controlled clinical trials have 
been developed to verify the effects of supplementation 
with different concentrations of DHA and EPA on cognitive 
function in patients presenting mild cognitive deficiency or 
AD to different degrees. Overall, results have been subtle or 
absent.114–118 Among other factors, such unsatisfactory results 
might be attributed to the fact that almost none of these stud-
ies consider the ApoE genotype profile and, therefore, the 
genetic susceptibility for AD development.119
Reviews of studies of transgenic animal models have 
compiled a series of beneficial results in response to omega-3 
consumption, mainly regarding synaptic alterations, Aβ accu-
mulation, Tau protein alteration, and cognitive deficits. These 
models are important for the knowledge of the mechanisms 
of actions, including the following: positive regulation of 
neurotrophic factors, inhibition of the inflammatory cascade, 
reduction in oxidative damage (especially through an increase 
in glutathione reductase activity and reduction in oxidized 
protein accumulation, lipid peroxidation, and ROS levels), 
and actions on cellular membrane properties and cellular 
signaling pathways.112,120
Given the importance of the aforementioned studies, 
Calon112 highlights relevant key points that – in addition to 
the promising results shown – have been raised and must 
be carefully evaluated to avoid premature conclusions about 
the efficiency of omega-3 consumption. In the opinion of 
Calon112 it is essential to verify whether advanced age or 
AD impairs the capacity of DHA to cross the blood–brain 
barrier and reach the brain tissues. The author also stresses 
the need to better define the therapeutic roles of DHA and 
EPA, specifying their relative contributions and their specific 
mechanisms of action. Finally, three aspects are empha-
sized: (1) the effects of omega-3 fatty acids are potentially 
related to a modification of disease potential, and for this 
reason, it is not expected that they present effects on late 
AD; (2) the consideration that AD is not a homogenous 
disease and might present itself in more than one form, 
meaning that each individual could respond differently to 
treatment; and (3) taking into account the high intragroup 
variability in the responses to a specific omega-3 fatty acid 
supplementation.
Strategies to prevent micronutrient 
deficiencies
Considering a pronounced population aging process and 
consequent increase in the prevalence of dementia, the search 
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for strategies to prevent or postpone the onset of diseases 
such as AD is necessary. Diet is an intensively modifiable 
lifestyle factor that is likely to work toward a reduction in 
the risk of developing AD. Faced with the results discussed 
in this review, it seems reasonable to affirm that individu-
als’ nutritional status must be carefully considered upon 
the occurrence of disease and throughout one’s entire life. 
Despite the necessity of additional studies, the adoption of 
healthy eating habits that allow the maintenance of blood 
levels of several micronutrients remains at the top of dietary 
recommendations.
On the other hand, it must be stressed that most studies 
have investigated nutrients in their isolated forms, and it is 
known that there is a great complexity in the human diet 
that is strongly influenced by synergy or antagonism among 
components.121 Therefore, some studies of whole foods and 
of dietary patterns have been performed. Dietary patterns 
that are predominantly composed of whole foods instead 
of refined foods, as well as the Mediterranean and Dietary 
Approaches to Stop Hypertension diets, have been associ-
ated with an improvement in cognitive performance and 
with a reduced risk of the development of mild cognitive 
impairment, of a progression from mild cognitive impair-
ment to AD, and of the onset of AD itself.122–127 On the other 
hand, some studies report a failure of these dietary patterns 
to improve cognitive performance and reduce the risk of 
AD occurrence.128,129 Therefore, there is a consensus in the 
literature that at the present time, definitive dietary recom-
mendations are not plausible. However, lifestyle changes, 
including greater consumption of fats derived from fish, 
vegetable oils, nonstarchy vegetables, and fruits with low 
glycemic indexes – in addition to reduced consumption of 
foods containing additional sugars and a moderate intake 
of alcoholic beverages – are recommended not only to 
reduce dementia risks, but also for a series of other diet-
responsive conditions.130
Furthermore, it is known that AD might relate to altered 
taste and the ability to chew and swallow, resulting in 
changes in dietary patterns, which often tend to acquire 
monotonous characteristics. As a consequence, ingested 
foods might not be sufficient to provide an individual’s 
entire nutritional need, so supplementation becomes an 
important strategy to ensure an adequate nutritional supply. 
However, it is important to evaluate the patient’s biochemi-
cal and clinical profile before starting supplementation. 
Moreover, it is suggested that the dosage used should 
comply with established recommendations to ensure 
patient safety.
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